180 Life Sciences Corporate Media Kit

18 Fibrosis & Anti-TNF Clinical Development Plan* Anti-TNF DD phase 2b/3 trial Ph 2b results Ph 3 results Q4 2026 POCD results Q1 2024 Frozen Shoulder (FS) Preparation POCD Preparation Approval to do trial* Anti-TNF FS phase 2 trial Therapeutic development Target identified Anti-TNF POCD phase 2 trial Approval to do trial* Phase 3 Results Proceed to registration or further phase 3 trial if required Target discovery in human liver fibrosis 2020 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 *Based on current proposals. No regulatory approvals sought from appropriate authorities at this time. **Regulatory approvals obtained from the MHRA (UK) and the relevant accredited ethics committee to perform clinical trials in the UK. No meetings have been held with, and no applications or requests for approval have been submitted to the FDA for any products at this time. 180 Life Sciences Corp. www.180lifesciences.com Q4 2020